Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Illumina Secures CE Mark for VeriSeq NIPT

Illumina Secures CE Mark for VeriSeq NIPT

Apr 10, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Illumina announced today that it has launched its noninvasive prenatal test, VeriSeq NIPT, as a CE-marked in vitro diagnostic in Europe. The test screens for trisomies 21, 18, and 13, as well as some sex chromosomal disorders at 10 weeks' gestation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Terminates Qiagen Acquisition Agreement

  2. Laboratory, Provider Organizations Urge HHS to Update COVID-19 Testing Prioritization Guidelines

  3. Sherlock Bio, Dartmouth-Hitchcock Health Partner on Clinical Study of Sherlock CRISPR SARS-CoV-2 Kit

  4. UK Reports First Results From At-Home Antibody Testing Program for SARS-CoV-2

  5. Solaris Diagnostics, Alpha Genomix Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.